|
AGI Dermatics
AGI Dermatics has been recognized as the world leader in DNA repair technology for more than 20 years. The company is at the forefront of dynamic biomolecular research in dermatology and skin care products. AGI Dermatics is developing a topical skin lotion for repair of sun damage to skin. Phase III clinical trials have demonstrated that this drug significantly reduces the incidence of pre-malignancies and skin cancer.
The company supplies ingredients for cosmetic products that are found in countless brands around the globe.
Cytokine PharmaSciences, Inc.
Cytokine PharmaSciences, Inc., is a private global biopharmaceutical company dedicated to the development of novel technologies and targets which it in-licenses from third parties and subsequently out-licenses for commercialization.
Products developed by Cytokine PharmaSciences are based on its technology platform, a controlled-release drug delivery system, or its expertise in cytokine inhibition. In addition to manufacturing a best-selling obstetrical product currently on the worldwide market, the Company has a robust, diversified pipeline of compounds in the Pre-clinical and Clinical Phases of development.
Kiadis (formerly Celmed)
Kiadis is a private Canadian biopharmaceutical company developing breakthrough products to treat cancer.
The Company applies rational drug design and pharmacogenomic concepts to improve cancer patient care, an approach that offers significant potential both in terms of efficacy and safety to the patient. Kiadis’s two lead products, Theralux™ and NB1011, are currently in Phase I/II clinical development. Theralux™, a photodynamic-based therapy, is being evaluated in three therapeutic areas: the prevention of graft-versus-host disease (GvHD), the treatment of autoimmune diseases by extracorporeal photochemotherapy (ECP) and the eradication of cancerous cells from bone marrow transplants in non-Hodgkin’s lymphoma (NHL). NB1011, a "Trojan horse solution" to treat cancer, exploits the over-expression of the thymidylate synthase (TS) enzyme to destroy cancer cells. Kiadis is currently planning a second Phase I/II study in various types of solid tumor cancers exhibiting high levels of TS, such as colorectal, lung, ovarian and breast cancer.
Pipex Pharmaceuticals
Developer of Gastrointestinal Products
Vectramed
VectraMed, Inc. is focused on developing a new generation of site-directed sustained release formulations of pharmaceutical and biotechnology agents. Through application of its Tissue-Activated Drug Delivery™ technology (TADD™), drugs can be delivered directly to the site of disease. The TADD dosage forms can last from days to weeks.
The initial products being developed by VectraMed are derived from FDA-approved drugs for chronic inflammatory diseases (such as rheumatoid arthritis) and cancer. The Company is also developing TADD formulations of patented novel anti-fibrotic compounds for indications such as pulmonary hypertension, restenosis and scleroderma.
The Company markets its technology directly to pharmaceutical and biotechnology companies through development agreements for each clinical indication.
|
